---
company: Cellectis S.A.
ticker: CLLS
form: 6-K
filed: 2026-11-09
accepted: 2026-11-09T21:35:03+00:00
accession: 0001171843-26-007273
source: https://www.sec.gov/Archives/edgar/data/1627281/000117184326007273/
---

# Cellectis (CLLS) Q3 2026 earnings

## Header

- Company: Cellectis S.A.
- Reported: 2026-11-09 16:35 AMC ET
- Source: 6-K only — accession 0001171843-26-007273, Exhibit 99.1
- Verdict: Net loss narrowed to $39.6 million on $11.0 million revenue, driven by a $27.3 million swing in net financial results and a $24.9 million increase in operating loss.

## Headline numbers

| Metric | Actual | YoY | QoQ | 6-K location |
|---|---|---|---|---|
| Revenue | $11.0 million | -59.1% | — | Ex. 99.1, income statement |
| EPS (GAAP) | -$0.40 | — | — | Ex. 99.1, income statement |
| Net income | -$39.6 million | -$2.3 million | — | Ex. 99.1, income statement |
| Adj. EBITDA | -$49.0 million | -$5.8 million | — | Ex. 99.1, income statement |
| Adj. EBITDA margin | -446.4% | +2.3 pp | — | Ex. 99.1, income statement |

## Revenue breakdown

not stated in the 6-K

## Margins and costs

- Gross margin: not stated in the 6-K
- Operating expenses: $63.5 million (+$8.5 million YoY)
- One-offs in the quarter: Net financial gain of $9.2 million (vs. $18.1 million loss YoY); Tax rate of -0.2% (vs. 0.0% YoY)
- Effective tax rate: -0.2% (vs. 0.0% YoY)
- Non-GAAP bridge: Adds back stock-based compensation ($3.9 million) and depreciation/amortization ($1.0 million) to GAAP net loss to arrive at Adj. EBITDA.

## KPIs

| Metric | Actual | Prior quarter | Prior year | Change |
|---|---|---|---|---|
| Cash and cash equivalents | $35.6 million | $35.6 million | — | — |
| Fixed-term deposits | $131.1 million | $131.1 million | — | — |
| Total cash and deposits | $166.7 million | $166.7 million | — | — |
| Cash runway | Through Q4 2027 | Through Q4 2027 | — | — |

## Guidance

not stated in the 6-K

## What drove it

- Revenue story: Revenue of $11.0 million decreased $16.4 million YoY, driven by lower activity levels under the AZ JRCA Research Plans.
- EPS story: The net loss narrowed by $2.3 million YoY primarily due to a $27.3 million improvement in net financial results, offset by a $24.9 million increase in operating loss.
- One-off check: Net financial gain of $9.2 million (vs. $18.1 million loss YoY) and a tax rate of -0.2% (vs. 0.0% YoY).

## The good

- Cash and cash equivalents of $35.6 million and fixed-term deposits of $131.1 million.
- Net financial gain of $9.2 million (vs. $18.1 million loss YoY).

## The bad

- Net loss of $39.6 million.
- Operating loss of $49.0 million.
- Revenue of $11.0 million, down 59.1% YoY.

## The ugly

- none

## Open questions

- The filing does not provide a breakdown of the $16.8 million cash received from customers in the cash flow statement.
- The filing does not provide a breakdown of the $4.9 million interest received on financial investments in the cash flow statement.

## Full release

### Cellectis (CLLS) earnings release, November 9, 2026

Cellectis S.A. (CLLS) · Form 6-K · Filed 2026-11-09 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1627281/000117184326007273/)

Cellectis to Report Third Quarter Financial Results on November 12, 2026

NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a genome engineering company developing genetic medicines for diseases that today demand a lifetime of treatment, will report financial results for the third quarter 2026 ending September 30, 2026 on Thursday, November 12, 2026 after the close of the U.S. market.

The publication will be followed by an investor conference call and webcast on Friday, November 13, 2026, at 8:00 a.m. ET / 2:00 p.m. CET. The call will include the Company’s third quarter 2026 results and an update on business activities. Details for the call are as follows:

Dial in information:

Toll Free US & Canada: +1-833-354-6854

US/International Toll: +1-785-838-9343

Conference ID: CLLSQ3

Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1780016&tp_key=925efa50d7

About Cellectis

Cellectis is a genome engineering company developing genetic medicines for diseases that today demand a lifetime of treatment. Leveraging decades of expertise in programmable DNA-binding proteins, the Company has built a differentiated genome engineering platform spanning gene editing, base editing, epigenetic editing and transcriptional regulation. By delivering the genomic intervention each disease requires, Cellectis is advancing a new generation of genetic medicines designed to move beyond disease management and toward lasting therapeutic impact.

Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X.

For further information on Cellectis, please contact:

Media contacts:

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contact:

Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com

Attachment

Q3 2026 announcement PR_ENGLISH.pdf (https://ml.globenewswire.com/Resource/Download/0b14096f-beec-4196-95d8-43124085acf4)
